Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Share News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.675
Bid: 1.65
Ask: 1.70
Change: 0.025 (1.52%)
Spread: 0.05 (3.03%)
Open: 1.65
High: 1.95
Low: 1.65
Prev. Close: 1.65
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: BAT falls on sales miss; Entain hit by MGM remark

Thu, 09th Feb 2023 09:13

(Alliance News) - Stock prices in London opened higher on Thursday, as investors digested a mixed set of UK company earnings.

The FTSE 100 index opened up 46.46 points, 0.6%, at 7,931.63. The FTSE 250 was 32.18 points, 0.2%, at 20,335.99, and the AIM All-Share was up just 0.1 of a point at 883.32.

The Cboe UK 100 was up 0.6% at 793.36, the Cboe UK 250 down 0.1% at 17,737.05, and the Cboe Small Companies was up 0.1% at 14,173.52.

In European equities on Thursday, the CAC 40 in Paris was up 1.1%, while the DAX 40 in Frankfurt was 1.2% higher.

Europe's largest economy saw inflation speed up slightly at the beginning of the year, according to preliminary figures.

Destatis said consumer prices in Germany rose 1.0% in January from the month before, reversing a 0.8% monthly decline in December. Annual inflation ticked up slightly to 8.7% from 8.6% at the end of 2022.

In Zurich, Credit Suisse fell 5.9%. The troubled Swiss lender posting an annual net loss of CHF7.29 billion, widening several-fold from CHF1.65 billion in 2021. It was the firm's biggest annual loss since the global financial crisis.

Net revenue plunged 34% to CHF14.92 billion from CHF22.70 billion.

Credit Suisse said its 2022 results were "significantly affected by the challenging macro and geopolitical environment with market uncertainty and client risk aversion", affecting client activity across all of its conditions.

Equities in New York had struggled on Wednesday. The Dow Jones Industrial Average closed down 0.6%, the S&P 500 down 1.1% and the Nasdaq Composite down 1.7%.

This came in the wake of several hawkish comments from Federal Reserve officials, stoking fears of persisted high interest rates and potential further hikes.

In comments reported by Bloomberg, Fed Vice Chair John Williams advocated for a "sufficiently restrictive stance of policy", adding that interest rates were "barely into restrictive territory".

"We're going to need to maintain that for a few years to make sure we get inflation to 2%, and then eventually over time we'll get interest rates presumably back to more normal levels," Williams said.

Fed Governor Christopher Waller added: "It might be a long fight, with interest rates higher for longer than some are currently expecting."

Meanwhile, Minneapolis Fed President Neel Kashkari warned there was "not yet much evidence, in my judgment, that the rate hikes that we've done so far are having much effect on the labour market".

Despite the hawkish rhetoric, the dollar was softer in early trade.

Sterling was quoted at USD1.2127, higher than USD1.2084 at the London equities close on Wednesday. The euro traded at USD1.0757, higher than USD1.0734. Against the yen, the dollar was quoted at JPY130.99, down from JPY131.29.

In the FTSE 100, Asia-focused bank Standard Chartered was the top performer, up 7.6%, while gambling operator Entain shed 11%.

In an earnings call on Wednesday, US casino operator MGM Resorts International confirmed it is no longer considering a takeover of Entain. "The simple answer on Entain is no; we've moved on," said MGM CEO Bill Hornbuckle.

Entain had rebuffed a takeover bid from MGM back in 2021. The two firms operate the BetMGM joint-venture together in the US.

AstraZeneca rose 4.1%, as the pharmaceutical firm swung to an annual profit.

Astra said total revenue in 2022 rose by 19% to USD44.35 billion from USD37.42 billion a year before, or by 24% at constant currency. Growth came from all therapy areas, as well as the addition of Alexion.

It swung to a pretax profit of USD2.50 billion from a loss of USD265 million, while core earnings per share jumped 26% to USD6.66. The pharmaceutical maker saw a weaker fourth quarter, however, as revenue fell by 7% to USD11.21 billion and core EPS fell by 17% to USD1.38. The lower revenue in the quarter was partly due to the decline in Vaxzevria, Astra said. Revenue excluding Vaxzevria rose 17%.

Looking ahead, Astra expects revenue in 2023 to grow at low-to-mid single-digit percentages at constant currency, or by low double-digit percentages excluding Covid-19 medicines. Core EPS is expected to see high single-digit to low double-digit growth.

Shore Capital said Astra's fourth-quarter EPS beat consensus. While Astra's forward guidance was in line with expectations, it "might disappoint" investors, the broker said.

British American Tobacco was down 4.1%. BAT reported a marginal rise in profit for 2022, as the cigarette maker navigated an "increasingly challenging" economic environment, but it noted that momentum in New Category was "strong".

In 2022, revenue grew 7.7% to GBP27.65 billion from GBP25.68 billion, despite lower volumes. The figure was below Vuma-cited market consensus of USD28.02 billion.

Cigarettes and tobacco heating products volumes fell by 4.2%. Pretax profit was up just 1.7% to GBP9.32 billion in 2022 from GBP9.16 billion in 2021.

It improved its total dividend by 1.0% to 217.80 pence from 215.60p a year earlier.

Looking ahead to 2023, BAT expects global tobacco industry volume to fall by around 2%. It expects mid-single figure constant currency adjusted earnings per share growth, which will be weighted towards the second half.

Unilever added 0.6%

The consumer goods firm said annual turnover rose 15% year-on-year to EUR60.07 billion from EUR52.44 billion, as pretax profit rose 21% to EUR10.34 billion from EUR8.56 billion. Underlying sales growth was 9.0%, driven by price growth, given that volumes fell 2.1%. In 2023, Unilever expects to deliver strong underlying sales growth.

Underlying price growth is expected to remain high, with volumes to fall in the first half, but said it is "too early to say" whether volumes will see positive growth in the second half.

Unilever expects 2023 underlying sales growth to be at least in the upper half of a 3% to 5% range.

"Despite sharp rises in material costs, we have prioritised stepping up our brand and marketing investment," said CEO Alan Jope.

According to interactive investor's Richard Hunter, the increased marketing spend shows Unilever "recognises the importance of keeping its brands in the mind of consumers". This is "despite price increases which run the risk of alienating cost-conscious shoppers".

In the FTSE 250, cybersecurity AI firm Darktrace rose 4.5%, as it closed its "largest deal-to-date".

The "multi-million dollar, multi-year" contract was signed with an unnamed "major" provider of critical infrastructure services.

Watches of Switzerland shed 5.7% in early trade.

The luxury watch firm reported double-digit growth in its financial third quarter ended January 29, as revenue rose 17% year-on-year to GBP407 million from GBP348 million. This was driven by luxury watches, "where demand continues to exceed supply".

For the whole of financial 2023, Watches expects to bring in revenue of GBP1.50 billion to GBP1.55 billion, with adjusted earnings before interest and tax to be between GBP163 million to GBP175 million. The guidance is on a pre-IFRS 16 basis, with a constant exchange rate applied to the fourth quarter. CEO Brian Duffy reports the firm's expansion into Europe is seeing "positive" early trading.

On AIM, Genedrive surged 34%.

The molecular diagnostics company said the UK's National Institute for Health & Care Excellence has preliminarily recommended its antiobiotic-induced hearing loss test for use in the National Health Service.

NICE's final guidance will follow a public consultation period, which will close on February 21.

In Asia on Thursday, the Nikkei 225 index closed down 0.1%. In China, the Shanghai Composite rose 1.2%, and the Hang Seng index in Hong Kong added 1.6%. The S&P/ASX 200 in Sydney closed down 0.5%.

Gold was quoted at USD1,884.81 an ounce early Thursday, higher than USD1,878.10 on Wednesday. Brent oil was trading at USD85.27 a barrel, edging up from USD84.01.

In the economic calendar, the US will publish its weekly unemployment insurance claims report at 1330 GMT.

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
9 Feb 2023 11:19

AIM WINNERS & LOSERS: Zytronic hit by electronic component shortages

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
9 Feb 2023 10:36

Genedrive hearing loss test recommended by UK health department body

(Alliance News) - Genedrive PLC on Thursday said the UK National Institute for Health & Care Excellence has preliminarily recommended its antibiotic hearing loss test, the MT-RNR1 ID kit.

Read more
3 Feb 2023 10:26

AIM WINNERS & LOSERS: 88 Energy surges; Petro Matad plans fundraise

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
29 Dec 2022 21:58

IN BRIEF: Genedrive shareholders vote down pre-emption rights power

Genedrive PLC - Manchester-based molecular diagnostics company - Reports that 21% of its shareholders voted against resolution 3 for the reappointment Tom Lindsay as a director at its annual general meeting on Thursday. 32% of its shareholders voted against resolution 5 for the reappointment of David Budd as a director, and 25% of shareholders voted against resolution 6 for the reappointment of Ian Gilham as a director. Adds that 25% of shareholders voted against resolution 10, to authorise the directors to allot equity securities in the capital.

Read more
22 Dec 2022 15:44

UK shareholder meetings calendar - next 7 days

Friday 23 December 
Plexus Holdings PLCAGM
Wildcat Petroleum PLCAGM
Monday 26 December 
no events scheduled 
Tuesday 27 December 
Zambeef Products PLCAGM
Wednesday 28 December 
Evrima PLCAGM
Greencare Capital PLCGM re proposed name change
Lift Global Ventures PLCGM re proposed expansion within the energy sector
Thursday 29 December 
Amte Power PLCAGM
ADVFN PLCAGM
Genedrive PLCAGM
Hotel Chocolat Group PLCAGM
Lekoil LtdEGM re proposed settlement and name change
Online Blockchain PLCAGM
PetroNeft Resources PLCAGM
SkinBioTherapeutics PLCAGM
  
Copyright 2022 Alliance News Ltd. All Rights Reserved.

Read more
21 Nov 2022 12:19

Genedrive shares slump as loss widens on lack of Covid-19 revenue

(Alliance News) - Genedrive PLC on Monday reported a substantially widened pretax loss as revenue slumped due to a lack of Covid-19 revenue.

Read more
21 Nov 2022 11:15

AIM WINNERS & LOSERS: Real Good Food secures turnaround funds

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
14 Nov 2022 14:32

UK earnings, trading statements calendar - next 7 days

Tuesday 15 November 
AdEPT Technology Group PLCHalf Year Results
BAE Systems PLCTrading Statement
Gear4Music PLCHalf Year Results
Imperial Brands PLCFull Year Results
Land Securities Group PLCHalf Year Results
Melrose Industries PLCTrading Statement
Ninety One PLC and LtdHalf Year Results
R&Q Insurance Holdings LtdQ1 Results
Speedy Hire PLCHalf Year Results
Vesuvius PLCTrading Statement
Vodafone Group PLCHalf Year Results
Wincanton PLCHalf Year Results
Workspace Group PLCHalf Year Results
Wednesday 16 November 
Aristocrat Leisure LtdFull Year Results
Bridgepoint Group PLCTrading Statement
British Land Co PLCHalf Year Results
Castings PLCHalf Year Results
CMC Markets PLCHalf Year Results
Enteq Technologies PLCHalf Year Results
Experian PLCHalf Year Results
Hill & Smith PLCTrading Statement
Mediclinic International PLCHalf Year Results
Nightcap PLCFull Year Results
Premier Foods PLCHalf Year Results
Renold PLCHalf Year Results
Sage Group PLCFull Year Results
Schroder Global Real Estate SecuritiesHalf Year Results
Schroder Real Estate Investment Trust LtdHalf Year Results
SSE PLCHalf Year Results
Thursday 17 November 
Burberry Group PLCHalf Year Results
Close Brothers Group PLCTrading Statement
Fuller, Smith & Turner PLCHalf Year Results
Grainger PLCFull Year Results
Great Portland Estates PLCHalf Year Results
Halma PLCHalf Year Results
Integrated Diagnostics Holdings PLCQ3 Results
Intermediate Capital Group PLCHalf Year Results
International Distributions Services PLCHalf Year Results
Investec PLC and LtdHalf Year Results
Keller Group PLCTrading Statement
Kier Group PLCTrading Statement
Mitie Group PLCHalf Year Results
Pershing Square Holdings LtdQ3 Results
Redcentric PLCHalf Year Results
Seraphim Space Investment Trust PLCQ1 Results
Spirax-Sarco Engineering PLCTrading Statement
Syncona LtdHalf Year Results
Tyman PLCTrading Statement
Virgin Money UK PLCFull Year Results
Zytronic PLCFull Year Results
Friday 18 November 
Bank of Cyprus Holdings PLCQ3 Results
Liontrust Asset Management PLCHalf Year Results
Monday 21 November 
Big Yellow Group PLCHalf Year Results
Compass Group PLCFull Year Results
Dialight PLCTrading Statement
Diploma PLCFull Year Results
Equipmake Holdings PLCFull Year Results
Genedrive PLCFull Year Results
Molten Ventures PLCHalf Year Results
MTI Wireless Edge LtdQ3 Results
NextEnergy Solar Fund LtdHalf Year Results
Polar Capital Holdings PLCHalf Year Results
Sirius Real Estate LtdHalf Year Results
SysGroup PLCHalf Year Results
Virgin Money UK PLCFull Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
5 Oct 2022 11:40

Genedrive shares surge as pre-submission for MT-RNR1 filed to FDA

(Alliance News) - Genedrive PLC on Wednesday said it has started engagement with the US Food & Drug Administration to progress the approval of its MT-RNR1 product range into the US.

Read more
5 Oct 2022 11:03

Genedrive engages with US FDA over infant test

(Sharecast News) - Near-patient molecular diagnostics company Genedrive has started engaging with the US Food and Drug Administration (FDA), it announced on Wednesday, to progress the regulatory approval of its 'MT-RNR1 ID Kit' into the United States.

Read more
26 Sep 2022 14:24

Genedrive says its "world first" test has been accelerated by NICE

(Alliance News) - Genedrive PLC on Monday said that its Genedrive MT-RNR1 test has been accelerated by the UK's National Institute for Health & Clinical Excellence.

Read more
26 Sep 2022 14:10

Genedrive test to go through new, faster NICE process

(Sharecast News) - Molecular diagnostics technology company Genedrive announced on Monday that the UK's National Institute for Health and Clinical Excellence (NICE) has transferred the evaluation of its 'MT-RNR1' test to a new 'early value assessment programme'.

Read more
22 Aug 2022 11:48

Genedrive's CYP2C19 ID Kit included in UK's NICE assessment

(Alliance News) - Genedrive PLC on Monday said the UK's National Institute for Health & Clinical Excellence has begun an evaluation of CYP2C19 genotype testing for Clopidogrel treatment.

Read more
22 Aug 2022 10:39

Another Genedrive test to be assessed by NICE

(Sharecast News) - Near-patient molecular diagnostics company Genedrive announced on Monday that the UK's National Institute for Health and Clinical Excellence (NICE) has started an evaluation of CYP2C19 genotype testing for clopidogrel treatment, via a new NICE diagnostics assessment programme (DAP).

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.